Delbiopharm and Marina Biotech will partner on the development of treatments against bladder cancer using Marina's RNAi technology. Delbio will pay $25 M in R&D milestones and Marina will also receive royalties on sales of any therapeutic reaching commericialization.
In additon to bladder cancer, Marina's pipeline has therapies aimed at treating familial adenomatous polyposis and hepatocellular carcinoma. See Fierce Biotech.
Posted by Bruce Lehr Feb 5th 2011.